Neogen Corporation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Neogen Corporation (NEOG) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $5.90 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-05-31 was $1.50M, a 1400.00% increase year-over-year.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-02-28 was $2.18M, a 82.30% increase year-over-year.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-05-31 was $100.00K, a 93.45% decline year-over-year.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-02-28 was $1.20M, a 36.11% decline year-over-year.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2026 was $5.90M, a 16.90% decline from fiscal 2025.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $7.10M, a 26.79% increase from fiscal 2024.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $5.60M, a 49.96% decline from fiscal 2023.
- Neogen Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $11.19M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $3.68M derived: sum of 2 quarters · filed 2026-07-30 | $5.90M 10-K · filed 2026-07-30 | |||
| 2026-02-28 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | $4.40M 10-Q · filed 2026-04-09 | ||||
| 2025-11-30 | $2.22M 10-Q · filed 2026-01-08 | |||||
| 2025-05-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $1.30M derived: sum of 2 quarters · filed 2026-07-30 | $7.10M 10-K · filed 2026-07-30 | $7.11M 10-K · filed 2025-07-30 | ||
| 2025-02-28 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-04-09 | $7.00M 10-Q · filed 2026-04-09 | $6.98M 10-Q · filed 2025-04-09 | |||
| 2024-11-30 | $5.80M 10-Q · filed 2026-01-08 | |||||
| 2024-05-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-30 | $3.40M derived: sum of 2 quarters · filed 2026-07-30 | $5.60M 10-K · filed 2026-07-30 | $5.56M 10-K · filed 2024-07-30 | ||
| 2024-02-29 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-09 | $4.07M 10-Q · filed 2025-04-09 | ||||
| 2023-11-30 | $2.20M 10-Q · filed 2025-01-15 | |||||
| 2023-05-31 | $11.19M 10-K · filed 2025-07-30 | |||||
| 2022-05-31 | $0.00 10-K · filed 2022-07-27 | |||||
| 2021-05-31 | $0.00 10-K · filed 2021-07-30 | |||||
| 2020-05-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-30 | $0.00 derived: sum of 2 quarters · filed 2020-07-30 | $0.00 derived: sum of 3 quarters · filed 2020-07-30 | $0.00 10-K · filed 2020-07-30 | ||
| 2020-02-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-04-03 | $0.00 derived: sum of 2 quarters · filed 2020-04-03 | $0.00 10-Q · filed 2020-04-03 | |||
| 2019-11-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-12-27 | $0.00 10-Q · filed 2019-12-27 | ||||
| 2019-08-31 | $0.00 10-Q · filed 2019-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |